|
|
Association of miRNA-122-binding site polymorphism at the interleukin-1 α gene and its interaction with hepatitis B virus mutations with hepatocellular carcinoma risk |
Du Yan,Han Xue2,Pu Rui,Xie Jiaxin,Zhang Yuwei,Cao Guangwen1,() |
Department of Epidemiology, Second Military Medical University, Shanghai 200433, China
Division of Chronic Diseases, Center for Disease Control and Prevention of Yangpu District, Shanghai 200090, China |
|
|
Abstract This study was designed to investigate the contribution of miRNA-122-binding site polymorphism at the IL-1A gene and its multiplicative interactions with hepatitis B virus (HBV) mutations in the risk of hepatocellular carcinoma (HCC). A total of 1021 healthy controls, 302 HBV surface antigen (HBsAg) seroclearance subjects, and 2011 HBsAg-positive subjects (including 1021 HCC patients) were enrolled in this study. Quantitative PCR was used to genotype rs3783553. HBV mutations were determined by direct sequencing. Multivariate logistic regression analyses were performed to test the associations of rs3783553, mutations, and their interactions with the risk of HCC. No significant association was found between rs3783553 and the risk of HCC among healthy controls, HBsAg seroclearance subjects, HBsAg-positive subjects without HCC, and all controls. Additionally, rs3783553 was not significantly associated with chronic HBV infection, liver cirrhosis, HBV e antigen seroconversion, abnormal alanine aminotransferase, and high viral load (>104 copies/ml). However, the TTCA insertion allele of rs3783553 was significantly associated with an increased frequency of HBV C7A mutation compared with homozygous TTCA deletion carriers [(del/ins+ ins/ins) vs. del/del, adjusted odds ratio (OR)=1.48, 95% confidence interval (CI)=1.09-2.02, P=0.013]. Multiplicative interaction of rs3783553 with HBV preS deletion significantly reduced the risk of HCC in males, with an adjusted OR of 0.64 (95% CI=0.42-0.98; P=0.041) after age and HBV genotype were adjusted. Although rs3783553 did not significantly affect genetic susceptibility to HBV-related HCC, its variant allele may predispose the host to selecting HBV C7A mutation during evolution and significantly reduce the risk of HCC caused by HBV preS deletion. This study provides an insight into the complex host-virus interaction in HBV-induced hepatocarcinogenesis and is helpful in determining HBsAg-positive subjects who are likely to develop HCC.
|
Keywords
hepatocellular carcinoma (HCC)
interaction
miRNA-122-binding site
IL-1A
rs3783553
hepatitis B virus (HBV) mutations
|
Corresponding Author(s):
Cao Guangwen
|
Online First Date: 04 May 2014
Issue Date: 21 May 2014
|
|
1 |
Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol2011; 26(2): 221-227 doi: 10.1111/j.1440-1746.2010.06576.x pmid: 21070361
|
2 |
Tan YJ. Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol2011; 17(44): 4853-4857 doi: 10.3748/wjg.v17.i44.4853 pmid: 22171125
|
3 |
Yin J, Zhang H, He Y, Xie J, Liu S, Chang W, Tan X, Gu C, Lu W, Wang H, Bi S, Cui F, Liang X, Schaefer S, Cao G. Distribution and hepatocellular carcinoma-related viral properties of hepatitis B virus genotypes in Mainland China: a community-based study. Cancer Epidemiol Biomarkers Prev2010; 19(3): 777-786 doi: 10.1158/1055-9965.EPI-09-1001 pmid: 20160279
|
4 |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin2012; 62(1): 10-29 doi: 10.3322/caac.20138 pmid: 22237781
|
5 |
Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN, Iloeje UH, Chen CJ. Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol2011; 29(27): 3643-3650 doi: 10.1200/JCO.2011.36.2335 pmid: 21859997
|
6 |
Fang ZL, Sabin CA, Dong BQ, Ge LY, Wei SC, Chen QY, Fang KX, Yang JY, Wang XY, Harrison TJ. HBV A1762T, G1764A mutations are a valuable biomarker for identifying a subset of male HBsAg carriers at extremely high risk of hepatocellular carcinoma: a prospective study. Am J Gastroenterol2008; 103(9): 2254-2262 doi: 10.1111/j.1572-0241.2008.01974.x pmid: 18844615
|
7 |
Yang HI, Yeh SH, Chen PJ, Iloeje UH, Jen CL, Su J, Wang LY, Lu SN, You SL, Chen DS, Liaw YF, Chen CJ; REVEAL-HBV Study Group.Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst2008; 100(16): 1134-1143 doi: 10.1093/jnci/djn243 pmid: 18695135
|
8 |
Chou YC, Yu MW, Wu CF, Yang SY, Lin CL, Liu CJ, Shih WL, Chen PJ, Liaw YF, Chen CJ. Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Gut2008; 57(1): 91-97 doi: 10.1136/gut.2006.114066 pmid: 17502344
|
9 |
Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst2009; 101(15): 1066-1082 doi: 10.1093/jnci/djp180 pmid: 19574418
|
10 |
Zhang Q, Cao G. Genotypes, mutations, and viral load of hepatitis B virus and the risk of hepatocellular carcinoma: HBV properties and hepatocarcinogenesis. Hepat Mon2011; 11(2): 86-91 pmid: 22087123
|
11 |
Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J, Zhang J, Han J, Wang L, Liu Y, Wang F, Zhao J, Zhang Q, Ni W, Wang H, Cao G. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol2011; 106(1): 81-92 doi: 10.1038/ajg.2010.399 pmid: 20959817
|
12 |
Yin J, Xie J, Zhang H, Shen Q, Han L, Lu W, Han Y, Li C, Ni W, Wang H, Cao G. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol2010; 45(10): 1063-1071 doi: 10.1007/s00535-010-0253-1 pmid: 20419326
|
13 |
Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol2011; 17(38): 4258-4270 doi: 10.3748/wjg.v17.i38.4258 pmid: 22090781
|
14 |
Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett2009; 286(1): 52-59 doi: 10.1016/j.canlet.2008.12.003 pmid: 19147276
|
15 |
Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer2012; 48(13): 1977-1987 doi: 10.1016/j.ejca.2012.01.015 pmid: 22325840
|
16 |
Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol2009; 24(8): 1352-1357 doi: 10.1111/j.1440-1746.2009.05985.x pmid: 19702903
|
17 |
Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J Gastroenterol2009; 15(46): 5761-5769 doi: 10.3748/wjg.15.5761 pmid: 19998495
|
18 |
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu MS, Lin JT. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA2012; 308(18): 1906-1914 doi: 10.1001/2012.jama.11975 pmid: 23162861
|
19 |
Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol2013; 31(29): 3647-3655 doi: 10.1200/JCO.2012.48.5896 pmid: 24002499
|
20 |
Apte RN, Dotan S, Elkabets M, White MR, Reich E, Carmi Y, Song X, Dvozkin T, Krelin Y, Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev2006; 25(3): 387-408 doi: 10.1007/s10555-006-9004-4 pmid: 17043764
|
21 |
Zhang Q, Pu R, Du Y, Han Y, Su T, Wang H, Cao G. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets. Cancer Lett2012; 321(1): 1-12 doi: 10.1016/j.canlet.2012.03.011 pmid: 22425745
|
22 |
Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT. Identification of deregulated miRNAs and their targets in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol2012; 18(38): 5442-5453 doi: 10.3748/wjg.v18.i38.5442 pmid: 23082062
|
23 |
Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, Wang Q, Ge C, Chen T, Zhao Y, Liang L, Li J, He X. Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IκB kinase α and TAB3 in hepatocellular carcinoma. Hepatology2013; 58(2): 654-666 doi: 10.1002/hep.26378 pmid: 23487264
|
24 |
Yu Z, Li Z, Jolicoeur N, Zhang L, Fortin Y, Wang E, Wu M, Shen SH. Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res2007; 35(13): 4535-4541 doi: 10.1093/nar/gkm480 pmid: 17584784
|
25 |
Sonkoly E, Ståhle M, Pivarcsi A. MicroRNAs and immunity: novel players in the regulation of normal immune function and inflammation. Semin Cancer Biol2008; 18(2): 131-140 doi: 10.1016/j.semcancer.2008.01.005 pmid: 18291670
|
26 |
Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, Landi S, Zhou Y, Liu H. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis2009; 30(12): 2064-2069 doi: 10.1093/carcin/bgp283 pmid: 19917630
|
27 |
Han Y, Pu R, Han X, Zhao J, Zhang Y, Zhang Q, Yin J, Xie J, Shen Q, Deng Y, Ding Y, Li W, Li J, Zhang H, Cao G. Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS ONE2013; 8(3): e58564 doi: 10.1371/journal.pone.0058564 pmid: 23516510
|
28 |
Xie J, Zhang Y, Zhang Q, Han Y, Yin J, Pu R, Shen Q, Lu W, Du Y, Zhao J, Han X, Zhang H, Cao G. Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma. Hepatology2013; 57(6): 2369-2377 doi: 10.1002/hep.26303 pmid: 23386590
|
29 |
Xie JX, Zhao J, Yin JH, Zhang Q, Pu R, Lu WY, Zhang HW, Wang HY, Cao GW. Association of novel mutations and haplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma. Front Med China2010; 4(4): 419-429 doi: 10.1007/s11684-010-0160-0 pmid: 21104161
|
30 |
Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, Ma F, Huang W, Yu L, Yue W, Wang Z, Li P, Zhang Y, Liang R, Wei Z, Cui Y, Xie W, Cai M, Yu X, Yuan Y, Xia X, Zhang X, Yang H, Qiu W, Yang J, Gong F, Chen M, Shen H, Lin D, Zeng YX, He F, Zhou G. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet2010; 42(9): 755-758 doi: 10.1038/ng.638 pmid: 20676096
|
31 |
Li S, Qian J, Yang Y, Zhao W, Dai J, Bei JX, Foo JN, McLaren PJ, Li Z, Yang J, Shen F, Liu L, Yang J, Li S, Pan S, Wang Y, Li W, Zhai X, Zhou B, Shi L, Chen X, Chu M, Yan Y, Wang J, Cheng S, Shen J, Jia W, Liu J, Yang J, Wen Z, Li A, Zhang Y, Zhang G, Luo X, Qin H, Chen M, Wang H, Jin L, Lin D, Shen H, He L, de Bakker PI, Wang H, Zeng YX, Wu M, Hu Z, Shi Y, Liu J, Zhou W. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet2012; 8(7): e1002791 doi: 10.1371/journal.pgen.1002791 pmid: 22807686
|
32 |
Clifford RJ, Zhang J, Meerzaman DM, Lyu MS, Hu Y, Cultraro CM, Finney RP, Kelley JM, Efroni S, Greenblum SI, Nguyen CV, Rowe WL, Sharma S, Wu G, Yan C, Zhang H, Chung YH, Kim JA, Park NH, Song IH, Buetow KH. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology2010; 52(6): 2034-2043 doi: 10.1002/hep.23943 pmid: 21105107
|
33 |
Jiang DK, Sun J, Cao G, Liu Y, Lin D, Gao YZ, Ren WH, Long XD, Zhang H, Ma XP, Wang Z, Jiang W, Chen TY, Gao Y, Sun LD, Long JR, Huang HX, Wang D, Yu H, Zhang P, Tang LS, Peng B, Cai H, Liu TT, Zhou P, Liu F, Lin X, Tao S, Wan B, Sai-Yin HX, Qin LX, Yin J, Liu L, Wu C, Pei Y, Zhou YF, Zhai Y, Lu PX, Tan A, Zuo XB, Fan J, Chang J, Gu X, Wang NJ, Li Y, Liu YK, Zhai K, Zhang H, Hu Z, Liu J, Yi Q, Xiang Y, Shi R, Ding Q, Zheng W, Shu XO, Mo Z, Shugart YY, Zhang XJ, Zhou G, Shen H, Zheng SL, Xu J, Yu L. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet2013; 45(1): 72-75 doi: 10.1038/ng.2483 pmid: 23242368
|
34 |
Du Y, Xie J, Chang W, Han Y, Cao G. Genome-wide association studies: inherent limitations and future challenges. Front Med2012; 6(4): 444-450 doi: 10.1007/s11684-012-0225-3 pmid: 23124883
|
35 |
He Y, Zhang H, Yin J, Xie J, Tan X, Liu S, Zhang Q, Li C, Zhao J, Wang H, Cao G. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis2009; 30(11): 1916-1922 doi: 10.1093/carcin/bgp226 pmid: 19797428
|
36 |
Yang ZH, Dai Q, Zhong L, Zhang X, Guo QX, Li SN. Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Mol Carcinog2011; 50(3): 208-214 doi: 10.1002/mc.20706 pmid: 21154765
|
37 |
Nicklin MJ, Weith A, Duff GW. A physical map of the region encompassing the human interleukin-1 alpha, interleukin-1 beta, and interleukin-1 receptor antagonist genes. Genomics1994; 19(2): 382-384 doi: 10.1006/geno.1994.1076 pmid: 8188271
|
38 |
Pan QW, Henry SD, Scholte BJ, Tilanus HW, Janssen HL, van der Laan LJ. New therapeutic opportunities for hepatitis C based on small RNA. World J Gastroenterol2007; 13(33): 4431-4436 pmid: 17724797
|
39 |
Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, Wu E, Ye X, Gao GF, Wang F, Chen Y, Duan Z, Meng S. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1) -modulated P53 activity. Hepatology2012; 55(3): 730-741 doi: 10.1002/hep.24809 pmid: 22105316
|
40 |
Li C, Wang Y, Wang S, Wu B, Hao J, Fan H, Ju Y, Ding Y, Chen L, Chu X, Liu W, Ye X, Meng S. Hepatitis B virus mRNA-mediated miR-122 inhibition upregulates PTTG1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol2013; 87(4): 2193-2205 doi: 10.1128/JVI.02831-12 pmid: 23221562
|
41 |
Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, Lim K, Wu T. Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology2013; 58(5): 1681-1692 doi: 10.1002/hep.26514 pmid: 23703729
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|